TrialAlimentary pharmacology & therapeutics2021

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.

Atsushi Nakajima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.